A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 (Bentracimab) With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
Latest Information Update: 25 Jan 2024
At a glance
- Drugs Bentracimab (Primary) ; Ticagrelor
- Indications Haemorrhage
- Focus Adverse reactions; Pharmacodynamics
- Sponsors PhaseBio Pharmaceuticals
- 19 Jan 2024 Status changed from recruiting to discontinued. The study was initially stopped because of Covid-19. Later, it was found that the PK data for the dose of 18000 mg (which was going to be tested in Cohort-5), would be available from the ongoing Phase 3 study of this drug. Hence, the study was terminated.
- 22 Dec 2021 Status changed from not yet recruiting to recruiting.
- 19 Aug 2021 New trial record